Lowers the risk of cardiovascular mortality and heart failure hospitalizations. ANDA 203894, held by Zydus Pharms. Metoprolol Succinate.
As of Nov 16, 2026, ANDA 203894 (Metoprolol Succinate), held by Zydus Pharms, was first approved by FDA on Mar 23, 2018, with 4 approved supplements and 0 published complete response letters.
Metoprolol succinate extended-release tablets, are a beta-adrenergic blocker indicated for the treatment of: Hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. Angina Pectoris. Heart Failure, to reduce the risk of cardiovascular mortality and heart failure hospitalizations in patients with heart failure 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 23, 2018 | Original application | Approved | None posted |
| Metoprolol SuccinateEQ 25MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 50MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 100MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 200MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Sep 21, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| May 5, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| May 5, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Oct 29, 2018 | Supplement 3Manufacturing | Approved | None posted |
| Mar 23, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters